Switch theme
Sign up to access all valuation multiples
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
2006
1.0K+
Last FY Revenue $408M
Last FY EBITDA -$326M
$10.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Ascendis Pharma achieved revenue of $408M and an EBITDA of -$326M.
Ascendis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ascendis Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $408M | XXX | XXX | XXX |
| Gross Profit | XXX | $359M | XXX | XXX | XXX |
| Gross Margin | XXX | 88% | XXX | XXX | XXX |
| EBITDA | XXX | -$326M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -80% | XXX | XXX | XXX |
| EBIT | XXX | -$313M | XXX | XXX | XXX |
| EBIT Margin | XXX | -77% | XXX | XXX | XXX |
| Net Profit | XXX | -$425M | XXX | XXX | XXX |
| Net Margin | XXX | -104% | XXX | XXX | XXX |
| Net Debt | XXX | $334M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ascendis Pharma's stock price is EUR 146 (or $164).
Ascendis Pharma has current market cap of EUR 8.8B (or $9.9B), and EV of EUR 9.1B (or $10.3B).
See Ascendis Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.3B | $9.9B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ascendis Pharma has market cap of $9.9B and EV of $10.3B.
Ascendis Pharma's trades at 25.1x EV/Revenue multiple, and -31.5x EV/EBITDA.
Equity research analysts estimate Ascendis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ascendis Pharma's P/E ratio is not available.
See valuation multiples for Ascendis Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.9B | XXX | $9.9B | XXX | XXX | XXX |
| EV (current) | $10.3B | XXX | $10.3B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 25.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -31.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -32.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -23.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -29.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAscendis Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.7M for the same period.
Ascendis Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ascendis Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ascendis Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -80% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 84% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 164% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ascendis Pharma acquired XXX companies to date.
Last acquisition by Ascendis Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Ascendis Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ascendis Pharma founded? | Ascendis Pharma was founded in 2006. |
| Where is Ascendis Pharma headquartered? | Ascendis Pharma is headquartered in Germany. |
| How many employees does Ascendis Pharma have? | As of today, Ascendis Pharma has 1.0K+ employees. |
| Who is the CEO of Ascendis Pharma? | Ascendis Pharma's CEO is Mr. Jan Moller Mikkelsen. |
| Is Ascendis Pharma publicy listed? | Yes, Ascendis Pharma is a public company listed on BER. |
| What is the stock symbol of Ascendis Pharma? | Ascendis Pharma trades under A71 ticker. |
| When did Ascendis Pharma go public? | Ascendis Pharma went public in 2015. |
| Who are competitors of Ascendis Pharma? | Similar companies to Ascendis Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ascendis Pharma? | Ascendis Pharma's current market cap is $9.9B |
| Is Ascendis Pharma profitable? | Yes, Ascendis Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
